Paper Details

  1. Home
  2. Paper Details

Pimavanserin for Psychosis in Parkinson's Disease-Related Disorders: A Retrospective Chart Review.

Author: ClaassenDaniel O, DarbyR Ryan, FarooqueAlma, SellersJessie

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Pimavanserin, a newly approved treatment for Parkinson's disease psychosis, is showing promise in real-world settings. However, more research is needed to fully understand its long-term efficacy and outcomes.
Paper Details　
Original Abstract of the Article :
Psychosis is common in Parkinson's disease-related disorders and is associated with significant morbidity. Pimavanserin is a newly approved treatment for Parkinson's disease psychosis, but real-world experience with pimavanserin has been limited by small sample sizes and limited assessment of longit...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6584229/

データ提供：米国国立医学図書館（NLM）

Pimavanserin for Psychosis in Parkinson's Disease-Related Disorders: A Retrospective Chart Review

Parkinson's disease-related disorders can be accompanied by psychosis, which significantly impacts patients' lives. This study examined the effectiveness of pimavanserin, a newly approved treatment for Parkinson's disease psychosis, through a retrospective chart review. The study found that pimavanserin showed promise in managing psychosis symptoms, but the small sample size and limited assessment of longitudinal outcomes limited the scope of the findings. Further research is needed to better understand the long-term effects of pimavanserin and its role in managing psychosis associated with Parkinson's disease.

A New Hope for Managing Parkinson's Disease Psychosis

This study offers encouraging preliminary evidence for the use of pimavanserin in managing psychosis in Parkinson's disease-related disorders. While the study's limitations require further investigation, the findings provide a glimmer of hope for improving the lives of patients struggling with this debilitating condition.

Navigating the Desert of Neurological Disorders

Parkinson's disease and its associated conditions present a unique challenge for healthcare providers and patients. This study reminds us that the desert of neurological disorders is vast and often unforgiving, but with continued research and innovation, we can find ways to manage these conditions and improve the well-being of patients.

Dr.Camel's Conclusion

This retrospective chart review provides preliminary evidence for the effectiveness of pimavanserin in managing psychosis associated with Parkinson's disease. While further research is needed, the findings suggest that pimavanserin may offer a valuable treatment option for patients struggling with this condition. Navigating the desert of neurological disorders requires a combination of patience, persistence, and a commitment to finding innovative solutions.

Date :
  1. Date Completed 2019-08-13
  2. Date Revised 2020-03-09
Further Info :

Pubmed ID

30924099

DOI: Digital Object Identifier

PMC6584229

Related Literature

Article Analysis
・Side Effects of pimavanserin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.